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ReportsOther than these Saudi Arabian children, there is 1 report of
LRPAP1-related high myopia in a Chinese 5-year-old boy homo-
zygous for the LRPAP1 mutation c.199delC (p.Gln67Serfs*8).3
Axial lengths were 32.59 mm and 32.24 mm, and visual acuities
were not provided. That patient was reported to have myopia
of 8.00, but this is inconsistent with his axial lengths of >30
mm. It is also inconsistent with our experience, as we have
found recessive LRPAP1 mutations typically to be associated
with cycloplegic refraction greater than 20, ranging from 17
to 32 with a median of 24 in our series.
The clinical and biometric features we describe in this report
characterize LRPAP1-related high myopia and should raise suspi-
cion for mutations in the gene. Other than dominant monogenic
forms of nonsyndromic high myopia (mutations in ZNF644, SCO2,
SLC39A5, P4HA2, or CCDC111), the majority of which have not
been carefully phenotyped to date, the other major monogenic
cause of high myopia in children is vitreoretinopathy.4 There are
several recognized forms of vitreoretinopathy associated with
high myopia.4 Most of these are autosomal dominant and can be
differentiated from LRPAP1-related high myopia by the presence
of vitreopathy or extraocular features. The most common
vitreoretinopathy associated with high myopia is Stickler
syndrome, characterized by midfacial hypoplasia, hearing loss,
arthropathy, juvenile lens opacity, and a propensity to retinal
detachment independent of the degree of myopia.4 Worldwide,
autosomal dominant mutations in collagen type II alpha 1
(OMIM þ120140, COL2A1) are the most common cause, but
mutations in other genes also can cause the phenotype.4 Some
patients with certain COL2A1 mutations can have an ocular
phenotype only.4 A less common but even more distinctive
vitreoretinopathy that is associated with high myopia is
Knobloch syndrome, characterized by occipital defect, high
myopia, and a distinctive vitreoretinopathy that includes smooth
irides, juvenile lens opacities, ectopia lentis, and a propensity to
retinal detachment independent of the degree of myopia.5
Recessive mutations in collagen type XVIII alpha 1 (OMIM
*120328, COL18A1) are the only known cause, and the
syndrome can be diagnosed by the presence of the
pathognomonic eye phenotype alone.5 As is the case for Stickler
syndrome, some patients with Knobloch syndrome have the
ocular phenotype only without extraocular features.5
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Ophthalmol 2012;96:890–5.Atopic Keratoconjunctivitis in
Children: Clinical Features and
DiagnosisDistinguishing between vernal keratoconjunctivitis (VKC) and
atopic keratoconjunctivitis (AKC) can be challenging. Historically,
AKC is rarely recognized as a diagnostic entity before puberty and
is thought to occur predominantly in adults. If a young patient were
to present with AKC-like symptoms and atopic dermatitis, they
might be diagnosed with VKC.1 The aim of this report was to
establish guidelines for distinguishing diagnosis between AKC
and VKC.
We conducted a case survey of 23 pediatric patients with severe
keratoconjunctivitis and atopic dermatitis who presented at 4 cen-
ters between 2011 and 2013. Mean ages at onset of symptoms and
at initial presentation to an ophthalmologist were 5.2 and 8.1 years,
respectively. All patients suffered from eczema and conjunctivitis/
keratitis, and the majority (74%) had a family history of atopy and
were affected by asthma and allergic rhinitis. The clinical features
of patients with AKC are presented in Table 1 and Figure 1
(available at www.aaojournal.org). The most prevalent clinical
features within this study were conjunctival hyperemia and
eczema, both of which were reported in 96% of patients. Other
clinical features include follicles, keratitis, and thickened dry
skin, which were present in 83% of patients. Papillae,
DennieeMorgan folds of the lower lid and blepharitis were
present in 65% of patients. Other clinical features such as giant
papillae (>1 mm diameter), DennieeMorgan double folds of the
upper lid, pseudoptosis, inﬁltration of the inferior conjunctiva,
HornereTrantas dots, and madarosis were present in 39% of
patients.435
Table 1. Clinical Features of Patients (n ¼ 23) with Atopic
Keratoconjunctivitis
Clinical Features Present, n (%)
Conjunctival hyperemia 22 (96)
Follicles 19 (83)
Papillae upper/lower 19 (83)
Giant papillae (> 1 mm diameter) 14 (61)
HornereTrantas dots (limbus) 9 (39)
Swelling of the limbus 9 (39)
Chemosis (conjunctival) 6 (26)
Limbaldneovascularization/corneal opaciﬁcation 11 (48)
Keratitis (superﬁcial punctate keratitis, shield ulcer,
ulcerations and corneal erosions)
20 (87)
Inﬁltration of inferior conjunctiva 12 (52)
DennieeMorgan
Double fold lower lid 18 (78)
Double fold upper lid 13 (57)
Pseudoptosis 12 (52)
Facial cutaneous ﬁssures (ears and canthus) 15 (65)
Anterior blepharitis 15 (65)
Posterior blepharitis 15 (65)
Eczema, thickened and dry eyelid 22 (96)
Thickened and dry skin
Facial 20 (87)
Body 19 (83)
Madarosis 10 (44)
Ophthalmology Volume 123, Number 2, February 2016In this report, AKC in children is deﬁned as the presence of
severe allergic conjunctivitis with atopic dermatitis that is diag-
nosed before 16 years of age. This may be accompanied by the
presence or absence of the following clinical features: conjunctival
hyperemia with eczema, madarosis, and blepharitis, with the
absence of HornereTrantas dots and giant papillae. The clinical
features described here may be used to deﬁne a grading system for
the identiﬁcation of AKC in children. No single clinical feature
viewed in isolation can accurately differentiate between AKC and
VKC.
Vernal keratoconjunctivitis is a rare, yet severe, form of allergic
conjunctivitis, estimated to affect 3.2 out of every 10 000 in-
habitants in western Europe.2 Vernal keratoconjunctivitis generally
ends at puberty; however, in some cases, it is thought that VKC
may “evolve” into AKC in adulthood.2 In the absence of typical
clinical signs of VKC, a child with atopic dermatitis may be
diagnosed with AKC and not VKC.1 Vernal keratoconjunctivitis
presents with highly speciﬁc symptoms, such as photophobia,
tearing, pseudoptosis, thick mucus discharge, and shield ulcers.2
Children with VKC may present with atopic dermatitis; however,
it is not a prerequisite for diagnosis.1 In contrast, evidence of
atopic dermatitis must be present for a diagnosis of AKC to be
made.1
In accordance with the ﬁndings reported herein, AKC in chil-
dren may be more prevalent than initially believed; in an epide-
miologic study of 134 patients with allergic conjunctivitis, 55% of
patients with AKC reported an onset of symptoms before 10 years
of age.3 In Japanese populations, VKC cases with any history of
atopic dermatitis is diagnosed as AKC, regardless of patient
age.4 In Europe, these cases would only be diagnosed as AKC if
the symptoms continued past puberty and occurred concurrently
with keratoconjunctivitis.1 The multifactorial assessment of key
clinical signs presented, taking into consideration the presence of436AKC-related clinical features and the absence of VKC-related
clinical features, in combination with a history of eczema and
conjunctivitis/keratitis, may promote accurate diagnosis of AKC in
children. Atopic keratoconjunctivitis and VKC differ in relation to
speciﬁc treatment needs. The dermatologic manifestations of AKC
need to be treated with emollients and demulcents and, if neces-
sary, corticosteroids. Furthermore, although immunomodulators
such as cyclosporine and tacrolimus are effective treatments for
both severe AKC and VKC, lower concentrations of these drugs
may be required in patients with AKC.5 These differences in the
optimal treatment of AKC and VKC highlight the importance of
early and accurate diagnosis, in informing effective treatment
strategies and improving patient outcomes.
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a speciIn Vivo Characterization of
Retinal Microvascular Network in
Multiple SclerosisMultiple sclerosis (MS) is an inﬂammatory demyelinating disorder
of the central nervous system characterized by progressive neuro-
degeneration. Current management aims to reduce the inﬂamma-
tion through immunomodulation. However, the effectiveness of
these treatments for preventing degeneration is unclear. Vascular
alterations, which may be caused by inﬂammatory cerebral endo-
theliopathy,1 could play a role in neurodegeneration. Indeed,
increased incidence of ischemic stroke and diffuse hypoperfusion
in normal-appearing white and gray matter have been reported in
MS patients.1 Thus, studying cerebral microvascular changes may
reveal the underlying pathophysiology that connects inﬂammation
and neurodegeneration. Because the retina is an extension of the
brain, the cerebral and retinal vasculature shares similar anatomic2. Retinal microvessel network analysis in patients with multiple sclerosi
d, circular zone (diameter ¼ 3.6 mm) was signiﬁcantly lower in MS patien
superior zone (B) was signiﬁcantly lower in the MS group (P ¼ 0.02). Am
- to 1.6-mm and 2.1- to 3.6-mm annular zones in comparison to the con
r operator curve (D) was 0.73 (P¼ 0.03) with a cutoff value of 1.5 for Dbo
ﬁcity of 70% for predicting MS microvasculature impairment. SD ¼ stanand physiologic features. Furthermore, thinning of the retinal
nerve ﬁber layer (RNFL) and of the ganglion layer are ocular
biomarkers of neurodegeneration in MS.2 Therefore,
characterizing retinal microvascular changes in MS may help to
determine the role of vascular dysfunction in neurodegeneration.
Direct measurement of the retinal vascular function can occur
through the transparent ocular media. We have developed a
method to quantitatively analyze noninvasive capillary perfusion
maps (nCPMs) obtained by the Retinal Function Imager (Optical
Imaging Ltd, Rehovot, Israel).3 This study was performed to
determine the macular microvascular network changes in patients
with relapsing and remitting MS.
We recruited 17 relapsing and remitting MS patients and
17 age- and gender-matched controls (Table 1; available at
www.aaojournal.org). Subjects with high refractive errors of
more than þ6.0 or 6.0 diopters (owing to the limit of the
imaging device), with any history of eye disease, or have been
on systemic corticosteroids within 3 months before the study
were excluded. Patients with a history of cerebral cardiovascular
disease, hypertension, diabetes, or kidney disease were also
excluded. The institutional review board approved this study and
every subject signed informed consent. Each MS patient had an
ophthalmic examination, including optical coherence tomography
imaging (Cirrus, Carl Zeiss Meditec, Dublin, CA) of the
peripapillary RNFL (200200 scan protocol). The nCPMs ats (MS) and controls. The microvessel fractal dimension (Dbox) in the fovea-
ts in comparison with controls (A). Among the quadrantal zones, the Dbox
ong the annular zones (C), the Dbox of MS groups was signiﬁcantly lower in
trol group in the same zones (P < 0.05). The area under the curve of the
x in the 2.1- to 3.6-mm annular zone. This provides a sensitivity of 77% and
dard deviation; SE ¼ standard error.
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